Alert Indications, Safety, and Warnings

Vanta™ SCS Neurostimulator  Recharge-free spinal cord stimulation

Vanta™ SCS gives you an advantage over pain. This revolutionary recharge-free device offers optimized longevity, personalized programming, and unmatched MRI access.

Download Brochure
Close-up product image of the Vanta PC Neurostimulator on white background
Alert Indications, Safety, and Warnings

Overview

Your advantage
over pain

Learn about Vanta™ SCS.

Product details

High-performance recharge-free neurostimulator

Vanta™ SCS is a high-performance recharge-free device offering optimized longevity.

  • Approximately 2x longer lasting than other devices at comparable settings*†
  • 5½–7½ years of recharge-free longevity estimated using actual 6-month DTM™ SCS endurance therapy programming data1
Vanta Platform

DTM™ SCS endurance therapy

DTM™ SCS endurance therapy is an energy modified differential target multiplexed therapy offering meaningful pain relief, satisfaction, and quality of life improvements.2

SEE MORE EVIDENCE


Clinical evidence for DTM™ SCS endurance therapy:

Meaningful pain relief

4.1 graph

reduction in VAS for
overall pain from
baseline to 6-months

Quality of life improvements

63 percent graph

had minimal to moderate disability at 3-months compared to only 16% at baseline

Therapy satisfaction

75 percent graph

of patients were
very or somewhat
satisfied with therapy

Unmatched full-body
MRI access

  • SureScan™ MRI technology allows MRI scans anywhere on the body‡ enabling diagnostic care.
  • Provide patients the same access as non-implanted patients‡ — now and in the future.
  • Shielded leads and proprietary device safeguards help patients safely get an MRI.‡
  • Access matters — 98% of patients are expected to need at least 1 MRI within 10 years of implant.3

Creating new connections

The Medtronic adaptor extension creates a connection between certain Boston Scientific™ or Nevro™ leads.§ This enables patients with existing leads to gain access to meaningful pain relief with DTM™ SCS endurance therapy offered with recharge-free convenience on Vanta™  INS or rapid recharge on Intellis™ INS.2 Patients with an Intellis™ INS may also choose superior pain relief with DTM™ SCS therapy.4

Learn more

Product specifications

Compatible with:

  • MyStim™ PC smart patient therapy app model A72200
  • Clinician programmer model CT900 with software app A71200 and trialing app A71300
  • 16-electrode Specify™ SureScan™ MRI surgical leads
  • Vectris™ SureScan™ MRI percutaneous leads
  • INJEX™ anchoring system models 97791 and 97792

Model specifications

Model 977006 
Channels 2
Width 1.1 cm (.44in) 
Battery Type Recharge-free 

Contact us 

U.S. clinician services
800-707-0933

*

Settings used from Proclaim™ clinician manual. Nominal settings 12 hours per day: 50-Hz frequency. 225-μs pulse width, and 5-mA amplitude at 500-ohms impedance. Compared to flagship model 3660.

†

Settings from Boston Scientific's Alpha™ IFU. Programmed at 4.1mA, 280us. 40Hz. 1 area, 730 Ohms, 2 contacts.

‡

Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.

§

Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

1

Provenzano, Amirdelfan, Grewal, et al. Modeling the impact of a differential target multiplexed derivative on rechargeable and recharge-free spinal cord stimulation systems using results from the Endurance Study. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.

2

Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.

3

Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537

4

Fishman M. Cordner H, Justiz R. et al. 12-Month Results from mu!ticenter, open-label. randomized controlled clmical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.1 3066.